Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms LIFE-C
- Sponsors AbbVie
- 12 Feb 2018 Planned End Date changed from 30 Apr 2018 to 26 Mar 2018.
- 12 Feb 2018 Planned primary completion date changed from 30 Apr 2018 to 26 Mar 2018.
- 24 Oct 2017 Results assessing quality of life in HCV patients presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases